MHRA-100776-PIP01-22-M01 (update)

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • Nemolizumab
Invented Name
Not yet defined
PIP Number MHRA-100776-PIP01-22-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Powder for solution for injection
Therapeutic area
Therapeutic area:
  • Dermatology
Conditions / Indications
Conditions / Indications:
  • Treatment of atopic dermatitis.
Route(s) of administration
Route(s) of administration:
  • Subcutaneous use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Nemolizumab.pdf
Published Date 24/08/2023